{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:14:03Z","timestamp":1788786843465,"version":"build-2803163510"},"reference-count":54,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Italian Medicine Agency","award":["E63C23000440002"],"award-info":[{"award-number":["E63C23000440002"]}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["20227C2YLA"],"award-info":[{"award-number":["20227C2YLA"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Monitoring medication adherence and main clinical outcomes changes in type 2 diabetes (T2D) is essential for optimal patient management. This study aimed to compute and evaluate medication adherence in its three process phases among T2D patients treated with oral antidiabetic (OAD) medications assessing association with main clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included newly diagnosed T2D patients initiating OAD therapy within 2015\u20132019 identified from the Nivel Primary Care Database (Nivel-PCD) in the Netherlands. Initiation was operationalised as \u22652 OAD prescriptions within follow-up. Implementation was quantified monthly using the Continuous Multiple-interval Measure of Medication Availability (CMA9). Group-based trajectory modelling (k-means via AdhereR) identified adherence patterns over 12 months. Persistence was assessed with a permissible-gap rule on the same 12-month series. Clinical measures (HbA1c, LDL cholesterol, blood pressure, BMI) were evaluated at baseline and at 12 months, and HbA1c trends were analysed over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 3,404 T2D patients started an OAD treatment, four distinct adherence clusters were identified: perfect adherence (70.1%), slow decline (13.3%), low adherence (10.6%), and slow increase (6.0%). Overall initiation was 99%. One-year persistence ranged from 26% (low adherence group) to 98.8% (perfect adherence group). Patients in the perfect-adherence group had higher baseline HbA1c but showed lower HbA1c and LDL levels over time compared with other groups. Blood pressure improved slightly in all groups. Changes in BMI were minimal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Adherence trajectories provide a dynamic view of patients\u2019 behaviour and are associated with better glycaemic and lipid control. High-risk patients were often in the perfect-adherence group and appeared to gain the highest clinical benefit. These results support routine adherence monitoring and targeted, trajectory-informed interventions in T2D care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0342056","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T18:28:30Z","timestamp":1771612110000},"page":"e0342056","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Medication adherence trajectories and association with risk factors and clinical outcomes in type 2 diabetes treatment"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3357-5655","authenticated-orcid":true,"given":"Sara","family":"Mucherino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Orlando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia","family":"Vervloet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvette","family":"Weesie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liset","family":"van Dijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Menditto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"issue":"1","key":"pone.0342056.ref001","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s12020-017-1517-9","article-title":"Glycemic control in type 2 diabetes: From medication nonadherence to residual vascular risk","volume":"61","author":"D Giugliano","year":"2018","journal-title":"Endocrine"},{"issue":"2","key":"pone.0342056.ref002","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/00005082-200201000-00003","article-title":"Risk factors for type 2 diabetes mellitus","volume":"16","author":"B Fletcher","year":"2002","journal-title":"J Cardiovasc Nurs"},{"key":"pone.0342056.ref003","doi-asserted-by":"crossref","first-page":"2040622321990264","DOI":"10.1177\/2040622321990264","article-title":"Optimal cut-off points for adherence measure among patients with type 2 diabetes in primary care clinics: A retrospective analysis","volume":"12","author":"MT Lim","year":"2021","journal-title":"Ther Adv Chronic Dis"},{"key":"pone.0342056.ref004","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.3389\/fphar.2018.01290","article-title":"A systematic review of medication adherence thresholds dependent of clinical outcomes","volume":"9","author":"PC Baumgartner","year":"2018","journal-title":"Front Pharmacol"},{"issue":"1","key":"pone.0342056.ref005","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/M18-0543","article-title":"ESPACOMP Medication Adherence Reporting Guideline (EMERGE)","volume":"169","author":"S De Geest","year":"2018","journal-title":"Ann Intern Med"},{"issue":"5","key":"pone.0342056.ref006","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04167.x","article-title":"A new taxonomy for describing and defining adherence to medications","volume":"73","author":"B Vrijens","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"pone.0342056.ref007","doi-asserted-by":"crossref","first-page":"104092","DOI":"10.1016\/j.ijmedinf.2020.104092","article-title":"Pitfalls of medication adherence approximation through EHR and pharmacy records: Definitions, data and computation","volume":"136","author":"A Galozy","year":"2020","journal-title":"Int J Med Inform"},{"issue":"12","key":"pone.0342056.ref008","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/pds.4334","article-title":"The myths of medication adherence","volume":"26","author":"WF Gellad","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"pone.0342056.ref009","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3389\/fphar.2013.00139","article-title":"Missing signposts on the roadmap to quality: A call to improve medication adherence indicators in data collection for population research","volume":"4","author":"BB Granger","year":"2013","journal-title":"Front Pharmacol"},{"issue":"1","key":"pone.0342056.ref010","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1208\/s12248-021-00644-3","article-title":"Machine learning and artificial intelligence in pharmaceutical research and development: A review","volume":"24","author":"S Kolluri","year":"2022","journal-title":"AAPS J"},{"issue":"9","key":"pone.0342056.ref011","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/MLR.0b013e3182984c1f","article-title":"Group-based trajectory models: a new approach to classifying and predicting long-term medication adherence","volume":"51","author":"JM Franklin","year":"2013","journal-title":"Med Care"},{"issue":"11","key":"pone.0342056.ref012","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.3390\/pharmaceutics15112568","article-title":"Longitudinal trajectory modeling to assess adherence to sacubitril\/valsartan among patients with heart failure","volume":"15","author":"S Mucherino","year":"2023","journal-title":"Pharmaceutics"},{"issue":"8","key":"pone.0342056.ref013","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.cardfail.2021.11.013","article-title":"Medication trajectory and treatment patterns in medicare patients with heart failure and reduced ejection fraction","volume":"28","author":"RJ Mentz","year":"2022","journal-title":"J Card Fail"},{"key":"pone.0342056.ref014","doi-asserted-by":"crossref","first-page":"25","DOI":"10.12688\/hrbopenres.13056.1","article-title":"Mapping the use of Group-Based Trajectory Modelling in medication adherence research: A scoping review protocol","volume":"3","author":"CA Walsh","year":"2020","journal-title":"HRB Open Res"},{"issue":"12","key":"pone.0342056.ref015","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011427","article-title":"Trajectories of oral anticoagulation adherence among medicare beneficiaries newly diagnosed with atrial fibrillation","volume":"8","author":"I Hernandez","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"pone.0342056.ref016","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/1074248419865287","article-title":"Trajectories of adherence to low-dose aspirin treatment among the french population","volume":"25","author":"A Ajrouche","year":"2020","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"24","key":"pone.0342056.ref017","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/j.jacc.2021.09.1370","article-title":"Longitudinal oral anticoagulant adherence trajectories in patients with atrial fibrillation","volume":"78","author":"S Salmasi","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"pone.0342056.ref018","doi-asserted-by":"crossref","DOI":"10.1093\/ije\/dyaf017","article-title":"Data resource profile: Nivel primary care database (Nivel-PCD), The Netherlands","volume":"54","author":"JW Vanhommerig","year":"2025","journal-title":"Int J Epidemiol"},{"key":"pone.0342056.ref019","year":"2022"},{"issue":"12","key":"pone.0342056.ref020","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-049487","article-title":"Identifying and delineating the type 2 diabetes population in the Netherlands using an all-payer claims database: Characteristics, healthcare utilisation and expenditures","volume":"11","author":"RJ Geurten","year":"2021","journal-title":"BMJ Open"},{"issue":"9","key":"pone.0342056.ref021","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2017.08.434","article-title":"Increased prevalence of diabetes in the netherlands is only partly explained by changes in age and sex over time","volume":"20","author":"J Overbeek","year":"2017","journal-title":"Value in Health"},{"issue":"2","key":"pone.0342056.ref022","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s41669-021-00308-0","article-title":"Delineating the type 2 diabetes population in the netherlands using an all-payer claims database: specialist care, medication utilization and expenditures 2016-2018","volume":"6","author":"RJ Geurten","year":"2022","journal-title":"Pharmacoecon Open"},{"key":"pone.0342056.ref023","year":"2022"},{"issue":"8","key":"pone.0342056.ref024","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.3390\/electronics9081295","article-title":"The k-means Algorithm: A comprehensive survey and performance evaluation","volume":"9","author":"M Ahmed","year":"2020","journal-title":"Electronics"},{"key":"pone.0342056.ref025","doi-asserted-by":"crossref","first-page":"80716","DOI":"10.1109\/ACCESS.2020.2988796","article-title":"Unsupervised K-means clustering algorithm","volume":"8","author":"KP Sinaga","year":"2020","journal-title":"IEEE Access"},{"issue":"2","key":"pone.0342056.ref026","first-page":"226","article-title":"Research on K-value selection method of k-means clustering algorithm","volume":"2","author":"C Yuan","year":"2019","journal-title":"J"},{"key":"pone.0342056.ref027","unstructured":"Netherlands General Practitioners Association (NHG). NHG-standaard diabetes mellitus type 2. 2018. richtlijnen.nhg.standaarden\/diabetesmellitus-type-2"},{"key":"pone.0342056.ref028","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3389\/fphar.2019.00383","article-title":"Beyond adherence thresholds: A simulation study of the optimal classification of longitudinal adherence trajectories from medication refill histories","volume":"10","author":"SS Allemann","year":"2019","journal-title":"Front Pharmacol"},{"key":"pone.0342056.ref029"},{"key":"pone.0342056.ref030","first-page":"1451","article-title":"AdhereR: An open science approach to estimating adherence to medications using electronic healthcare databases","volume":"264","author":"A Dima","year":"2019","journal-title":"Stud Health Technol Inform"},{"key":"pone.0342056.ref031"},{"issue":"10","key":"pone.0342056.ref032","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.3390\/ijerph17103742","article-title":"Initial therapy, regimen change, and persistence in a spanish cohort of newly treated type 2 diabetes patients: A retrospective, observational study using real-world data","volume":"17","author":"A Moreno-Juste","year":"2020","journal-title":"Int J Environ Res Public Health"},{"issue":"3","key":"pone.0342056.ref033","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/dom.14276","article-title":"Treatment persistence in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists in clinical practice in Sweden","volume":"23","author":"A-M Svensson","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"pone.0342056.ref034","article-title":"Medication persistence and its impact on type 2 diabetes","volume":"30","author":"JH Choe","year":"2024","journal-title":"Am J Manag Care"},{"key":"pone.0342056.ref035","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2147\/PPA.S92824","article-title":"Non-adherence to inhaled corticosteroids and the risk of asthma exacerbations in children","volume":"10","author":"EC Vasbinder","year":"2016","journal-title":"Patient Prefer Adherence"},{"issue":"8","key":"pone.0342056.ref036","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161381","article-title":"Medication adherence patterns after hospitalization for coronary heart disease. A population-based study using electronic records and group-based trajectory models","volume":"11","author":"J Librero","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"pone.0342056.ref037","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/dom.14603","article-title":"Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: A systematic literature review","volume":"24","author":"M Evans","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"pone.0342056.ref038","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/0145721715619038","article-title":"Medication adherence with diabetes medication: A systematic review of the literature","volume":"42","author":"K Capoccia","year":"2016","journal-title":"Diabetes Educ"},{"issue":"15","key":"pone.0342056.ref039","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1007\/s11606-024-08851-2","article-title":"Barriers and unmet educational needs regarding implementation of medication adherence management Across Europe: Insights from COST Action ENABLE","volume":"39","author":"G Hafez","year":"2024","journal-title":"J Gen Intern Med"},{"issue":"12","key":"pone.0342056.ref040","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1111\/bcp.16183","article-title":"Pan-European survey on medication adherence management by healthcare professionals","volume":"90","author":"M Kamusheva","year":"2024","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"pone.0342056.ref041","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.eprac.2025.06.012","article-title":"Trajectories of antidiabetic medication adherence in older adults and the effect of depression and anxiety symptoms","volume":"31","author":"G Ekanmian","year":"2025","journal-title":"Endocr Pract"},{"key":"pone.0342056.ref042","year":"2003"},{"issue":"5","key":"pone.0342056.ref043","doi-asserted-by":"crossref","first-page":"328","DOI":"10.24171\/j.phrp.2022.0168","article-title":"Effects of medication adherence interventions for older adults with chronic illnesses: A systematic review and meta-analysis","volume":"13","author":"HO Jeon","year":"2022","journal-title":"Osong Public Health Res Perspect"},{"issue":"3","key":"pone.0342056.ref044","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s40266-016-0433-7","article-title":"Improving medication adherence and health outcomes in older adults: An evidence-based review of randomized controlled trials","volume":"34","author":"ZA Marcum","year":"2017","journal-title":"Drugs Aging"},{"key":"pone.0342056.ref045","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fphar.2013.00091","article-title":"Determinants of patient adherence: A review of systematic reviews","volume":"4","author":"P Kardas","year":"2013","journal-title":"Front Pharmacol"},{"issue":"9","key":"pone.0342056.ref046","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1007\/s11606-016-3747-6","article-title":"Trajectories of diabetes medication adherence and hospitalization risk: A retrospective cohort study in a large state medicaid program","volume":"31","author":"W-H Lo-Ciganic","year":"2016","journal-title":"J Gen Intern Med"},{"issue":"3","key":"pone.0342056.ref047","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70174","article-title":"Longitudinal trajectories of antidiabetic medication adherence over 5\u2009years from treatment initiation-a swedish nationwide cohort study","volume":"18","author":"L Pazzagli","year":"2025","journal-title":"Clin Transl Sci"},{"issue":"3","key":"pone.0342056.ref048","doi-asserted-by":"crossref","first-page":"604","DOI":"10.2337\/dc21-1676","article-title":"Three sides to the story: Adherence trajectories during the first year of SGLT2 inhibitor therapy among medicare beneficiaries","volume":"45","author":"CE Hawley","year":"2022","journal-title":"Diabetes Care"},{"issue":"12","key":"pone.0342056.ref049","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0002730","article-title":"Routine health data describe adherence and persistence patterns for oral diabetes medication for a virtual cohort in the Khayelitsha sub-district of Cape Town, South Africa","volume":"3","author":"T Tamuhla","year":"2023","journal-title":"PLOS Glob Public Health"},{"issue":"9","key":"pone.0342056.ref050","first-page":"1138","article-title":"Medication adherence trajectories: A systematic literature review","volume":"26","author":"M Alhazami","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"pone.0342056.ref051","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/jan.15776","article-title":"Medication adherence trajectory of patients with chronic diseases and its influencing factors: A systematic review","volume":"80","author":"Y Chen","year":"2024","journal-title":"J Adv Nurs"},{"issue":"21","key":"pone.0342056.ref052","article-title":"Long-term medication adherence trajectories to direct oral anticoagulants and clinical outcomes in patients with atrial fibrillation","volume":"10","author":"J An","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"pone.0342056.ref053","first-page":"202","article-title":"Group-based trajectory models to identify sociodemographic and clinical predictors of adherence patterns to statin therapy among older adults","volume":"12","author":"A Vadhariya","year":"2019","journal-title":"Am Health Drug Benefits"},{"key":"pone.0342056.ref054","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.2147\/PPA.S106821","article-title":"Poor medication adherence in type 2 diabetes: Recognizing the scope of the problem and its key contributors","volume":"10","author":"WH Polonsky","year":"2016","journal-title":"Patient Prefer Adherence"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0342056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T18:28:45Z","timestamp":1771612125000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0342056"}},"subtitle":[],"editor":[{"given":"Yee Gary","family":"Ang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":54,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0342056","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]}}}